Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

NCT04421222 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

71

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated early due to a lack of improved efficacy.

Conditions

Prostate Cancer

Interventions

DRUG: EPI-7386 (QD)
DRUG: EPI-7386 (BID)
DRUG: Abiraterone acetate
DRUG: Apalutamide

Sponsor

ESSA Pharmaceuticals